Immutep Limited
NASDAQ:IMMPBiotechnology
+$0.00 today
- Market cap
- $55.01M
- Beta
- 2.24
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$0.06
Volume 3.10M
Average 13.46M
IMMP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Immutep LimitedNASDAQ: IMMP
Research & Development · Q2 FY2026 · quarter ended Dec 2025
Research & development remains negative
Q2 FY2026 research & development was A$0, compared with A$25.33M a year earlier. Over 3 fiscal years it compounded at +25.1% a year.
Context
- Research & development amounted to 1217.6% of revenue in FY2025, up 136.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
AUD · from the income statement
- Latest · FY2025
- 61.41M AUD
- Year-over-year change
- +47.8%
- 4-year CAGR
- +37.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 61.41M | +47.8% |
| FY2024 | 2024-06-30 | 41.55M | +44.3% |
| FY2023 | 2023-06-30 | 28.79M | -8.1% |
| FY2022 | 2022-06-30 | 31.34M | +81.8% |
| FY2021 | 2021-06-30 | 17.24M | — |
Research & Development vs competitors
How IMMP compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +47.8% is the 3rd highest of 11, against a peer median of +11.9%.
- Research & development amounts to 1217.6% of revenue for IMMP, versus a peer median of 329.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.01M USD | +44.8% | +53.7% | — | |
| LTM Mar 2026 | $143.25M USD | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $129.09M USD | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $101.99M USD | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $92.92M USD | +60.8% | +57.0% | — | |
| LTM Mar 2026 | $66.19M USD | -62.3% | -19.9% | 171.1% | |
| FY2025 | A$61.41M AUD | +47.8% | +25.1% | 1217.6% | |
| LTM Mar 2026 | €44.34M EUR | +12.6% | -7.1% | 329.9% | |
| LTM Mar 2026 | $36.32M USD | +88.9% | +13.6% | — | |
| LTM Mar 2026 | $19.19M USD | -29.2% | -8.6% | — | |
| LTM Mar 2026 | $18.13M USD | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding IMMP) | — | +11.9% | +0.6% | 329.9% | |
Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 3.86M | 170.37K | 3.51M | 3.84M | 5.04M |
| Cost of Revenue | 17.24M | 2.06M | 2.06M | 41.55M | 61.41M |
| Gross Profit | (13.37M) | (1.89M) | 1.44M | (37.7M) | (56.37M) |
| Gross Margin | -346.2% | -1111.2% | 41.2% | -981.4% | -1117.6% |
| Research & Development | 17.24M | 31.34M | 28.79M | 41.55M | 61.41M |
| Selling, General & Admin | 6.28M | 7.21M | 14.08M | 8.85M | 8.64M |
| Operating Expenses | 18.3M | 32.55M | 44.94M | 50.4M | 70.06M |
| Depreciation & Amortization | 1.89M | 1.84M | 1.86M | 2.01M | 2.13M |
| EBITDA | (17.77M) | (31.87M) | (39.57M) | (44.54M) | (62.88M) |
| EBITDA Margin | -460.0% | -18708.9% | -1128.8% | -1159.4% | -1246.6% |
| Operating Income | (31.68M) | (33.94M) | (77.69M) | (88.1M) | (126.42M) |
| Operating Margin | -820.0% | -19920.0% | -2216.0% | -2293.3% | -2506.5% |
| Interest Income | 105.33K | 224.52K | 939K | 3.88M | 5.25M |
| Interest Expense | 9.83K | 92.43K | 20.4K | 30.59K | 24.01K |
| Other Income / Expenses | 1.77M | 1.63M | 37.79M | 45.39M | 64.99M |
| Income Before Tax | (29.9M) | (32.21M) | (39.9M) | (42.72M) | (61.43M) |
| Pre-Tax Margin | -774.1% | -18906.5% | -1138.0% | -1111.9% | -1218.0% |
| Income Tax Expense | 33 | 34 | 0 | 0 | 0 |
| Net Income | (29.9M) | (32.21M) | (39.9M) | (42.72M) | (61.43M) |
| Net Margin | -774.1% | -18906.5% | -1138.0% | -1111.9% | -1218.0% |
| EPS (Basic) | (0.49) | (0.37) | (0.44) | (0.36) | (0.42) |
| EPS (Diluted) | (0.49) | (0.37) | (0.44) | (0.36) | (0.42) |
| Weighted Avg Shares | 60.43M | 86.23M | 90.06M | 119.99M | 145.58M |
| Weighted Avg Shares (Diluted) | 60.43M | 86.23M | 90.06M | 120.11M | 145.58M |
Immutep Limited
NASDAQ:IMMP
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.